NF-κB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies

被引:334
作者
Zhao, Jimmy L. [1 ]
Rao, Dinesh S. [1 ,2 ]
Boldin, Mark P. [3 ]
Taganov, Konstantin D. [4 ]
O'Connell, Ryan M. [1 ]
Baltimore, David [1 ]
机构
[1] CALTECH, Div Biol, Pasadena, CA 91125 USA
[2] Univ Calif Los Angeles, Dept Pathol & Lab Med, David Geffen Sch Med, Los Angeles, CA 90095 USA
[3] City Hope Natl Med Ctr, Dept Mol & Cellular Biol, Beckman Res Inst, Duarte, CA 91010 USA
[4] Regulus Therapeut Inc, San Diego, CA 92121 USA
基金
美国国家卫生研究院;
关键词
inflammation; cancer; myelofibrosis; noncoding RNA; IMMUNE-RESPONSES; MICRORNA SIGNATURES; TARGET; INFLAMMATION; ACTIVATION; MIR-146A; SYSTEM; CANCER; IRAK1; P50;
D O I
10.1073/pnas.1105398108
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
070301 [无机化学]; 070403 [天体物理学]; 070507 [自然资源与国土空间规划学]; 090105 [作物生产系统与生态工程];
摘要
MicroRNA miR-146a has been implicated as a negative feedback regulator of NF-kappa B activation. Knockout of the miR-146a gene in C57BL/6 mice leads to histologically and immunophenotypically defined myeloid sarcomas and some lymphomas. The sarcomas are transplantable to immunologically compromised hosts, showing that they are true malignancies. The animals also exhibit chronic myeloproliferation in their bone marrow. Spleen and marrow cells show increased transcription of NF-kappa B-regulated genes and tumors have higher nuclear p65. Genetic ablation of NF-kappa B p50 suppresses the myeloproliferation, showing that dysregulation of NF-kappa B is responsible for the myeloproliferative disease.
引用
收藏
页码:9184 / 9189
页数:6
相关论文
共 26 条
[1]
MicroRNAs: Target Recognition and Regulatory Functions [J].
Bartel, David P. .
CELL, 2009, 136 (02) :215-233
[2]
CONSTITUTIVE NF-KAPPA-B ACTIVATION, ENHANCED GRANULOPOIESIS, AND NEONATAL LETHALITY IN I-KAPPA-B-ALPHA-DEFICIENT MICE [J].
BEG, AA ;
SHA, WC ;
BRONSON, RT ;
BALTIMORE, D .
GENES & DEVELOPMENT, 1995, 9 (22) :2736-2746
[3]
BOLDIN MP, 2011, J EXP MED IN PRESS
[4]
Targeting NF-κB in hematologic malignancies [J].
Braun, T ;
Carvalho, G ;
Fabre, C ;
Grosjean, J ;
Fenaux, P ;
Kroemer, G .
CELL DEATH AND DIFFERENTIATION, 2006, 13 (05) :748-758
[5]
Braun T, 2006, BLOOD, V107, P1156
[6]
MicroRNA signatures in human cancers [J].
Calin, George A. ;
Croce, Carlo M. .
NATURE REVIEWS CANCER, 2006, 6 (11) :857-866
[7]
TARF6 is a signal transducer for interleukin-1 [J].
Cao, ZD ;
Xiong, J ;
Takeuchi, M ;
Kurama, T ;
Goeddel, DV .
NATURE, 1996, 383 (6599) :443-446
[8]
Nuclear factor κB as a target for new drug development in myeloid malignancies [J].
Cilloni, Daniela ;
Martinelli, Giovanni ;
Messa, Francesca ;
Baccarani, Michele ;
Saglio, Giuseppe .
HAEMATOLOGICA, 2007, 92 (09) :1224-1229
[9]
MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia [J].
Garzon, Ramiro ;
Volinia, Stefano ;
Liu, Chang-Gong ;
Fernandez-Cymering, Cecilia ;
Palumbo, Tiziana ;
Pichiorri, Flavia ;
Fabbri, Muller ;
Coombes, Kevin ;
Alder, Hansjuerg ;
Nakamura, Tatsuya ;
Flomenberg, Neal ;
Marcucci, Guido ;
Calin, George A. ;
Kornblau, Steven M. ;
Kantarjian, Hagop ;
Bloomfield, Clara D. ;
Andreeff, Michael ;
Croce, Carlo M. .
BLOOD, 2008, 111 (06) :3183-3189
[10]
Unravelling the complexities of the NF-κB signalling pathway using mouse knockout and transgenic models [J].
Gerondakis, S. ;
Grumont, R. ;
Gugasyan, R. ;
Wong, L. ;
Isomura, I. ;
Ho, W. ;
Banerjee, A. .
ONCOGENE, 2006, 25 (51) :6781-6799